Westchester Capital Management LLC decreased its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 83.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 189,844 shares of the health services provider's stock after selling 928,958 shares during the period. Amedisys makes up 0.9% of Westchester Capital Management LLC's investment portfolio, making the stock its 23rd largest holding. Westchester Capital Management LLC owned 0.58% of Amedisys worth $17,236,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Amedisys during the 4th quarter valued at about $83,061,000. Wealthfront Advisers LLC purchased a new position in shares of Amedisys during the 4th quarter worth approximately $72,970,000. Pacer Advisors Inc. raised its position in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock worth $50,679,000 after purchasing an additional 553,435 shares during the last quarter. Birnam Oak Advisors LP purchased a new stake in Amedisys in the 4th quarter valued at approximately $15,832,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Amedisys by 32.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 418,002 shares of the health services provider's stock valued at $37,950,000 after buying an additional 102,099 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.
Amedisys Trading Up 0.2 %
Shares of AMED traded up $0.17 during trading hours on Wednesday, hitting $94.89. The stock had a trading volume of 87,214 shares, compared to its average volume of 405,867. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market cap of $3.11 billion, a P/E ratio of 37.65, a P/E/G ratio of 1.78 and a beta of 0.89. The company's fifty day simple moving average is $92.32 and its 200 day simple moving average is $91.76. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95.
Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.12. The firm had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.03 EPS. Equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on AMED shares. Stephens reaffirmed an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research note on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $100.75.
Get Our Latest Analysis on AMED
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
